medigraphic.com
ISSN 2594-1526 (Digital)
ISSN 0028-3746 (Impreso)
Antes Revista del Instituto Nacional de Enfermedades Respiratorias

 Ver anteriores al 2010

2019, Número S1

Neumol Cir Torax 2019; 78 (S1)


Guía de Práctica Clínica Mexicana para el diagnóstico y tratamiento de la Enfermedad Pulmonar Obstructiva Crónica
GUÍA MEXICANA DE EPOC, 2020

Vázquez-García JC, Hernández-Zenteno RJ, Pérez-Padilla JR, Cano-Salas MC, Fernández-Vega M, Salas-Hernández J, Figueroa-Morales MA, Benítez-Pérez RE, Rendón-Pérez LA, Vázquez-Cortés J, Mejía-Ávila ME, Mayorga-Butrón JL, Acuña-Kaldman M, Barriga-Acevedo R, Bizarrón-Muro AR, Camargo-Ángeles R, Casillas-Suárez C, Castañeda-Hernández CO, Castañón-Rodríguez RP, Castillo-Sánchez JF, Cortés-Télles A, Díaz-Castañón JJ, Elizondo RA, Espitia-Hernández MG, García-Avilés MA, García-Torrentera R, González Aguirre JE, Guillén-Ortega FC, Herrera-García JC, Loustaunau-Andrade MA, Magdaleno MGE, Mendoza TLA, Padua-García J, Palomar-Lever A, Páramo-Arroyo RF, Toral-Freyre SC, Villegas-Elizondo JF, Zozoaga-Velázquez EG

Idioma: Español
Referencias bibliográficas: 111
Paginas: 4-76
Archivo PDF: 966.75 Kb.


RESUMEN

Introducción: La enfermedad pulmonar obstructiva crónica (EPOC) es una de las principales causas de muerte en México y en el mundo. Pese a que en los últimos años se ha alcanzado un gran progreso en su manejo y tratamiento, esto también ha conllevado una mayor complejidad. En México, es fundamental el desarrollo de guías de práctica clínica (GPC) que estén basadas en estándares internacionales para establecer recomendaciones a todos los niveles de atención. Objetivos: El objetivo fue desarrollar una GPC con recomendaciones clínicas desarrolladas de forma sistematizada para asistir a la toma de decisiones, tanto de médicos de todos los niveles de atención, como de pacientes, cuidadores de pacientes y todos los elaboradores de políticas públicas involucrados en el manejo de pacientes con enfermedad pulmonar obstructiva crónica. Material y métodos: Este documento fue desarrollado por parte de la Sociedad Mexicana de Neumología y Cirugía de Tórax en cumplimiento con los estándares internacionales como los descritos por el Instituto de Medicina de los Estados Unidos (IOM, por sus siglas en inglés). Se integró un Grupo de Desarrollo de la Guía (GDG) de manera interdisciplinaria, considerando la participación de neumólogos y metodólogos con experiencia en revisiones sistemáticas de la literatura y el desarrollo de GPC. De forma sistematizada, se consensuaron los alcances, las preguntas clínicas y se evaluaron otras Guías Internacionales sobre el tema. Se evaluó críticamente la calidad metodológica de esas GPC. A través del abordaje ADAPTE, se transculturizó la GPC a nuestro país y, finalmente, utilizando metodología de consenso formal de expertos, se desarrollaron las recomendaciones clínicas. Resultados: Se consensuaron 40 preguntas estructuradas clínicamente relevantes para el diagnóstico y tratamiento, así como las recomendaciones clínicas pertinentes y su texto de soporte. Las recomendaciones abarcan preguntas sobre diagnóstico y tratamiento. Conclusión: Esta GPC pretende proveer recomendaciones clínicas para el diagnóstico y manejo terapéutico de los distintos estadios de la EPOC basadas en evidencia científica, que asisten en el proceso de toma de decisiones compartidas y que esperamos contribuyan a mejorar la calidad de la atención clínica en las pacientes con EPOC.


REFERENCIAS (EN ESTE ARTÍCULO)

  1. Institute for Health Metrics and Evaluation (IHME). Findings from the Global Burden of Disease Study 2017. Seattle, WA: IHME; 2018. Disponible en: http://ghdx.healthdata.org/gbd-2017

  2. GOLD. Global Initiative for chronic obstructive lung disease global strategy for the diagnosis, management and prevention of chronic obstructive pulmonary disease (2019 REPORT). Disponible en: www.goldcopd.org

  3. Menezes AM, Perez-Padilla R, Jardim JR, et al. Chronic obstructive pulmonary disease in five Latin American cities (the PLATINO study): A prevalence study. Lancet 2005;366:1875-1881.

  4. Perez-Padilla R, Menezes AM. Chronic obstructive pulmonary disease in Latin America. Ann Glob Health 2019;85(1). doi:10.5334/aogh.2418.

  5. Lamprecht B, Soriano JB, Studnicka M, et al. Determinants of underdiagnosis of COPD in national and international surveys. Chest 2015;148(4):971-85.

  6. Talamo C, de Oca MM, Halbert R, et al. Diagnostic labeling of COPD in five Latin American cities. Chest 2007;131(1):60-67.

  7. Reynales-Shigematsu LM. Costos de atención médica de las enfermedades atribuibles al consumo de tabaco en América: revisión de la literatura. Salud Publica Mex 2006;48 suppl I:S190-S200.

  8. Fernández-Plata R, Martínez-Briseño D, García-Sancho F, et al. Métodos para la estimación de costos en salud de la EPOC: resultados basales. Neumol Cir Tórax 2016;75(1):4-11.

  9. Mannino DM. Counting costs in COPD. Chest 2015;147(1):3-5.

  10. Fervers B, Burgers JS, Voellinger R, et al. Guideline adaptation:an approach to enhance efficiency in guideline development and improve utilization. BMJ Qual Saf 2011;20(3):228-236.

  11. Brouwers MC, Kho ME, Browman GP, et al. AGREE II: advancing guideline development, reporting and evaluation in health care. CMAJ 2010;182(18):E839-E842.

  12. O’Sullivan D, Wilk S, Michalowski W, Farion K. Using PICO to align medical evidence with MDs decision making models. Stud Health Technol Inform.2013;192:1057. Available from: http://www.ncbi.nlm.nih.gov/pubmed/23920831

  13. SIGN. SIGN 50 a guideline developer’s handbook. Scottish Intercollegiate Guidelines Network. Healthcare improvement Scotland. 2011.

  14. Fink A, Kosecoff J, Chassin M, Brook RH. Consensus methods: characteristics and guidelines for use. Am J Public Health 1984;74(9):979-983.

  15. Secretaría de Salud [Internet]. Diagnóstico y tratamiento de la enfermedad pulmonar obstructiva crónica. 2009. Disponible en: http://www.cenetec.salud.gob.mx

  16. National Institute for Health and Care Excellence. Chronic obstructive pulmonary disease in over 16s: diagnosis and management. 2010.

  17. Montes de Oca M, López-Varela MV, Acuña A, et al. Guía de práctica clínica de la enfermedad pulmonar obstructiva crónica (EPOC) ALAT–2014: Preguntas y respuestas. Arch Bronconeumol; 51(8):403-416. Disponible en: http://dx.doi.org/10.1016/j.arbres.2014.11.017

  18. Miravitlles M, Soler-Cataluña JJ, Calle M, et al. Guía española de la enfermedad pulmonar obstructiva crónica (GesEPOC) 2017. Tratamiento farmacológico en fase estable. Arch Bronconeumol 2017;53(6):324-335.

  19. Wedzicha JA, Miravitlles M, Hurst JR, et al. Management of COPD exacerbations: a European Respiratory Society/American Thoracic Society guideline. Eur Respir J 2017;49:1600791. https://doi.org/10.1183/13993003.00791-2016

  20. Wedzicha JA, Calverley PMA, Albert RK, et al. Prevention of COPD exacerbations: a European Respiratory Society/American Thoracic Society guideline. Eur Respir J 2017;50(3): pii: 1602265. doi: 10.1183/13993003.02265-2016

  21. Yang IY, Brown JL, George J, et al. COPD-X Australian and New Zealand guidelines for the diagnosis and management of chronic obstructive pulmonary disease: 2017 update. Med J Aust 2017;207(10):436-442.

  22. Vazquez-Garcia JC, Balcázar-Cruz CA, Cervantes-Mendez LG, Mejía-Alfaro R, Cossío-Alcantara J, Ramírez-Venegas A. El leguaje de la disnea. Una visión desde el español de México. Arch Bronchoneumol 2006;42(5):211-217.

  23. Peto J. That the effects of smoking should be measured in pack-years: misconceptions 4. Br J Cancer 2012;107(3):406-7.

  24. She J, Yang P, Wang Y, et al. Chinese water-pipe smoking and the risk of COPD. Chest 2014;146(4):924-931.

  25. Yin P, Jiang CQ, Cheng KK, et al. Passive smoking exposure and risk of COPD among adults in China: the Guangzhou Biobank Cohort Study. Lancet 2007;370(9589):751-757.

  26. Wang C, Xu J, Yang L, et al. Prevalence and risk factors of chronic obstructive pulmonary disease in China (the China Pulmonary Health [CPH] study): National cross-sectional study. Lancet 2018;391(10131):1706-1717.

  27. Korn RJ, Dockery DW, Speizer FE, Ware JH, Ferris BGJ. Occupational exposures and chronic respiratory symptoms. A population-based study. Am Rev Respir Dis 1987;136(2):298-304.

  28. Borlee F, Yzermans CJ, Aalders B, et al. Air pollution from livestock farms is associated with airway obstruction in neighboring residents. Am J Respir Crit Care Med 2017;196(9):1152-1161.

  29. Guillien A, Puyraveau M, Soumagne T, et al. Prevalence and risk factors for COPD in farmers: a cross-sectional controlled study. Eur Respir J 2016;47(1):95-103.

  30. Oxman AD, Muir DC, Shannon HS, Stock SR, Hnizdo E, Lange HJ. Occupational dust exposure and chronic obstructive pulmonary disease. A systematic overview of the evidence. Am Rev Respir Dis 1993;148(1):38-48.

  31. Sunyer J, Zock JP, Kromhout H, et al. Lung function decline, chronic bronchitis, and occupational exposures in young adults. Am J Respir Crit Care Med 2005;172(9):1139-1145.

  32. Terho EO. Work-related respiratory disorders among Finnish farmers. Am J Ind Med 1990;18(3):269-272.

  33. Dalphin JC, Debieuvre D, Pernet D, et al. Prevalence and risk factors for chronic bronchitis and farmer’s lung in French dairy farmers. Br J Ind Med 1993;50(10):941-944.

  34. Terho EO, Husman K, Vohlonen I. Prevalence and incidence of chronic bronchitis and farmer’s lung with respect to age, sex, atopy, and smoking. Eur J Respir Dis Suppl 1987;152:19-28.

  35. Pope CA 3rd, Ezzati M, Dockery DW. Fine-particulate air pollution and life expectancy in the United States. N Engl J Med 2009;360(4):376-386.

  36. Zhou Y, Wang C, Yao W, et al. COPD in Chinese nonsmokers. Eur Respir J 2009;33(3):509-518.

  37. Andersen ZJ, Hvidberg M, Jensen SS, et al. Chronic obstructive pulmonary disease and long-term exposure to traffic-related air pollution: a cohort study. Am J Respir Crit Care Med 2011;183(4):455-461.

  38. Hu G, Zhou Y, Tian J, et al. Risk of COPD from exposure to biomass smoke: a metaanalysis. Chest 2010;138(1):20-31.

  39. McGeachie MJ, Yates KP, Zhou X, et al. Patterns of growth and decline in lung function in persistent childhood asthma. N Engl J Med 2016;374(19):1842-152.

  40. Lam KH, Jiang CQ, Jordan RE, et al. Prior TB, smoking, and airflow obstruction: a cross-sectional analysis of the Guangzhou Biobank Cohort Study. Chest 2010;137(3):593-600.

  41. Barnes PJ. Genetics and pulmonary medicine. 9. Molecular genetics of chronic obstructive pulmonary disease. Thorax 1999;54(3):245-252.

  42. Silverman EK. Genetics of chronic obstructive pulmonary disease. Novartis Found Symp 2001;234:45-64.

  43. Silverman EK, Chapman HA, Drazen JM, et al. Genetic epidemiology of severe, early-onset chronic obstructive pulmonary disease. Risk to relatives for airflow obstruction and chronic bronchitis. Am J Respir Crit Care Med 1998;157(6 Pt 1):1770-1778.

  44. Marciniak SJ, Lomas DA. What can naturally occurring mutations tell us about the pathogenesis of COPD? Thorax 2009;64(4):359-364.

  45. Jackson H, Hubbard R. Detecting chronic obstructive pulmonary disease using peak flow rate: cross sectional survey. BMJ 2003;327(7416):653-654.

  46. Benítez-Pérez RE, Torre-Bouscoulet L, Villca-Alá N, Del-Río-Hidalgo RF, Pérez-Padilla R, Vázquez-García JC, et al. Espirometría: recomendaciones y procedimiento. 2016;75(2):173-190.

  47. Pellegrino R, Viegi G, Brusasco V, Crapo RO, Burgos F, Casaburi R, et al. Interpretative strategies for lung function tests. Eur Respir J. 2005;26(5):948-968.

  48. Vazquez-García JC, Pérez-Padilla R. Manual de Espirometría. Ciudad de México, México. Graphimedic. 2019.

  49. Swanney MP, Ruppel G, Enright PL, Pedersen OF, Crapo RO, Miller MR, et al. Using the lower limit of normal for the FEV1/FVC ratio reduces the misclassification of airway obstruction. Thorax. 2008;63(12):1046-1051.

  50. Pérez-Rubio G, Jiménez-Valverde LO, Ramírez-Venegas A, et al. Prevalencia de variantes de alto riesgo de alfa-1 antitripsina en población mestiza mexicana y su relación con los valores de la función pulmonar. Arch Bronconeumol 2015;51(2):80-85.

  51. Westerdahl E, Arne M, Larsson M, Engman KO. Spirometry to motivate smoking cessation - a systematic review. Eur Respir J 2018;52(suppl 62):PA1734. Available from:http://erj.ersjournals.com/content/52/suppl_62/PA1734.abstract

  52. Consenso Mexicano. Guías para el diagnóstico y tratamiento de la EPOC. 2012;71(1).

  53. García-Gómez L, Sansores RH, Díaz VN, et al. Impacto del consejo breve para dejar de fumar. Salud Publica Mex 2015;57(5):366-367.

  54. Rusinowicz T, Zielonka TM, Zycinska K. Cardiac arrhythmias in patients with exacerbation of COPD. Adv Exp Med Biol 2017;1022:53-62.

  55. Km K, Mavergames C, Jae W, Kew KM, Mavergames C, Walters JE. Long-acting beta 2 -agonists for chronic obstructive pulmonary disease (Review) Long-acting beta 2 -agonists for chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2013;(10): CD010177. DOI: 10.1002/14651858.CD010177.pub2

  56. Nannini LJ, Lasserson TJ, Poole P. Combined corticosteroid and long-acting beta(2)-agonist in one inhaler versus long-acting beta(2)-agonists for chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2012;(9):CD006829.

  57. Nannini LJ, Poole P, Milan SJ, Kesterton A. Combined corticosteroid and long-acting beta(2)-agonist in one inhaler versus inhaled corticosteroids alone for chronic obstructive pulmonary disease. Cochrane database Syst Rev 2013;(8):CD006826.

  58. Brusselle G, Price D, Gruffydd-Jones K, et al. The inevitable drift to triple therapy in COPD: an analysis of prescribing pathways in the UK. Int J Chron Obstruct Pulmon Dis 2015;10:2207-2217.

  59. Welte T, Miravitlles M, Hernandez P, et al. Efficacy and tolerability of budesonide/formoterol added to tiotropium in patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2009;180(8):741-750.

  60. Singh D, Brooks J, Hagan G, Cahn A, O’Connor BJ. Superiority of “triple” therapy with salmeterol/fluticasone propionate and tiotropium bromide versus individual components in moderate to severe COPD. Thorax 2008;63(7):592-598.

  61. Jung KS, Park HY, Park SY, et al. Comparison of tiotropium plus fluticasone propionate/salmeterol with tiotropium in COPD: a randomized controlled study. Respir Med 2012;106(3):382-389.

  62. Hanania NA, Crater GD, Morris AN, Emmett AH, O’Dell DM, Niewoehner DE. Benefits of adding fluticasone propionate/salmeterol to tiotropium in moderate to severe COPD. Respir Med 2012;106(1):91-101.

  63. Frith PA, Thompson PJ, Ratnavadivel R, et al. Glycopyrronium once-daily significantly improves lung function and health status when combined with salmeterol/fluticasone in patients with COPD: the GLISTEN study, a randomized controlled trial. Thorax 2015;70(6):519-527.

  64. Siler TM, Kerwin E, Singletary K, Brooks J, Church A. Efficacy and safety of umeclidinium added to fluticasone propionate/salmeterol in patients with COPD: results of two randomized, double-blind studies. COPD 2016;13(1):1-10.

  65. Singh D, Papi A, Corradi M, et al. Single inhaler triple therapy versus inhaled corticosteroid plus long-acting beta2-agonist therapy for chronic obstructive pulmonary disease (TRILOGY): a double-blind, parallel group, randomised controlled trial. Lancet 2016;388(10048):963-973.

  66. Lipson DA, Barnacle H, Birk R, et al. Fulfil trial: once-daily triple therapy for patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med 2017;196(4):438-446.

  67. Karner C, Cates CJ. Combination inhaled steroid and long-acting beta (2)-agonist in addition to tiotropium versus tiotropium or combination alone for chronic obstructive pulmonary disease. Cochrane database Syst Rev 2011;(3):CD008532.

  68. Vestbo J, Papi A, Corradi M, et al. Single inhaler extrafine triple therapy versus long-acting muscarinic antagonist therapy for chronic obstructive pulmonary disease (TRINITY): a double-blind, parallel group, randomised controlled trial. Lancet 2017;389(10082):1919-1929.

  69. Lipson DA, Barnhart F, Brealey N, et al. Once-daily single-inhaler triple versus dual therapy in patients with COPD. N Engl J Med 2018;378(18):1671-1680.

  70. Papi A, Vestbo J, Fabbri L, et al. Extrafine inhaled triple therapy versus dual bronchodilator therapy in chronic obstructive pulmonary disease (TRIBUTE): a double-blind, parallel group, randomised controlled trial. Lancet 2018;391(10125):1076-1084.

  71. Bafadhel M, Peterson S, De Blas MA, et al. Predictors of exacerbation risk and response to budesonide in patients with chronic obstructive pulmonary disease: a post-hoc analysis of three randomised trials. Lancet Respir Med 2018;6(2):117-126.

  72. Pascoe S, Locantore N, Dransfield MT, Barnes NC, Pavord ID. Blood eosinophil counts, exacerbations, and response to the addition of inhaled fluticasone furoate to vilanterol in patients with chronic obstructive pulmonary disease: a secondary analysis of data from two parallel randomised controlled trials. Lancet Respir Med 2015;3(6):435-442.

  73. Sestini P, Renzoni E, Robinson S, Poole P, Ram FS. Short-acting beta 2 agonists for stable chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2002;(4):CD001495.

  74. O’Donnell DE, Aaron S, Bourbeau J, et al. Canadian Thoracic Society recommendations for management of chronic obstructive pulmonary disease - 2007 update. Can Respir J 2007;14 Suppl B:5B-32B.

  75. Tashkin DP. A review of nebulized drug delivery in COPD. Int J Chron Obstruct Pulmon Dis 2016;11:2585-2596.

  76. National Asthma Council Australia. Australian Asthma Handbook, Version 2.0. Melbourne: National Asthma Council Australia; 2016. [último acceso 07 Noviembre 2019] Disponible en: http://www.asthmahandbook.org.au

  77. Paediatric Society of New Zealand. Best practice evidence-based guideline: Management of asthma in children aged 1-15 years. 2005.

  78. Academy of Medicine of Malaysia, Malaysian Thoracic Society, Lung Foundation of Malaysia. Clinical practice guidelines for the management of childhood asthma. Kuala Lumpur: Academy of Medicine of Malaysia, Malaysian Thoracic Society, Lung Foundation of Malaysia. 2014.

  79. Ram FSF, Sestini P. Regular inhaled short acting beta2 agonists for the management of stable chronic obstructive pulmonary disease: Cochrane systematic review and meta-analysis. Thorax 2003;58(7):580-584.

  80. Burge PS, Calverley PM, Jones PW, Spencer S, Anderson JA, Maslen TK. Randomised, double blind, placebo controlled study of fluticasone propionate in patients with moderate to severe chronic obstructive pulmonary disease: the ISOLDE trial. BMJ 2000;320(7245):1297-1303.

  81. Watz H, Tetzlaff K, Wouters EFM, et al. Blood eosinophil count and exacerbations in severe chronic obstructive pulmonary disease after withdrawal of inhaled corticosteroids: a post-hoc analysis of the WISDOM trial. Lancet Respir Med 2016;4(5):390-398.

  82. Magnussen H, Disse B, Rodriguez-Roisin R, et al. Withdrawal of inhaled glucocorticoids and exacerbations of COPD. N Engl J Med 2014;371(14):1285-1294.

  83. Buhl R, Criee CP, Kardos P, et al. Dual bronchodilation versus triple therapy in the “real-life” COPD DACCORD study. Int J Chron Obstruct Pulmon Dis 2018;13:2557-2568.

  84. Horita N, Miyazawa N, Kojima R, et al. Chronic use of theophylline and mortality in chronic obstructive pulmonary disease: a meta-analysis. Arch Bronconeumol 2016;52(5):233-238.

  85. ZuWallack RL, Mahler DA, Reilly D, Church N, Emmett A, Rickard K, Knobil K. Salmeterol plus theophylline combination therapy in the treatment of COPD. Chest. 2001 Jun;119(6):1661-70.

  86. Devereux G, Cotton S, Fielding S, McMeekin N, Barnes PJ, Briggs A, et al. Effect of Theophylline as Adjunct to Inhaled Corticosteroids on Exacerbations in Patients With COPD: A Randomized Clinical Trial. JAMA. 2018 Oct;320(15):1548-1559.

  87. Ram FS, Jones PW, Castro AA, et al. Oral theophylline for chronic obstructive pulmonary disease. Cochrane database Syst Rev. 2002;(4):CD003902.

  88. Cosio BG, Shafiek H, Iglesias A, et al. Oral low-dose theophylline on top of inhaled fluticasone-salmeterol does not reduce exacerbations in patients with severe COPD: a pilot clinical trial. Chest 2016;150(1):123-130.

  89. Walters JAE, Tan DJ, White CJ, Gibson PG, Wood-Baker R, Walters EH. Systemic corticosteroids for acute exacerbations of chronic obstructive pulmonary disease. Cochrane database Syst Rev 2014;(9):CD001288.

  90. Walters JAE, Walters EH, Wood-Baker R. Oral corticosteroids for stable chronic obstructive pulmonary disease. Cochrane database Syst Rev 2005;(3):CD005374.

  91. Cazzola M, Rogliani P, Calzetta L, Hanania NA, Matera MG. Impact of mucolytic agents on COPD exacerbations: a pair-wise and network meta-analysis. COPD 2017;14(5):552-563.

  92. Ramos FL, Krahnke JS, Kim V. Clinical issues of mucus accumulation in COPD. Int J Chron Obstruct Pulmon Dis 2014;9:139-150.

  93. Aaron SD. Mucolytics for COPD: negotiating a slippery slope towards proof of efficacy. Eur Respir J 2017;50(4). pii:1701465.

  94. Turner RD, Bothamley GH. N-acetylcysteine for COPD: the evidence remains inconclusive. Lancet Respir Med 2014;2(4):e3.

  95. Brown WM. Treating COPD with PDE 4 inhibitors. Int J Chron Obstruct Pulmon Dis 2007;2(4):517-533.

  96. Martinez FJ, Calverley PM, Goehring UM, Brose M, Fabbri LM, Rabe KF. Effect of roflumilast on exacerbations in patients with severe chronic obstructive pulmonary disease uncontrolled by combination therapy (REACT): a multicentre randomised controlled trial. Lancet 2015;385(9971):857-866.

  97. Rabe KF, Calverley PMA, Martinez FJ, Fabbri LM. Effect of roflumilast in patients with severe COPD and a history of hospitalisation. Eur Respir J 2017;50(1).

  98. Dougall S, Bolt J, Semchuk W, Winkel T. Inhaler assessment in COPD patients: A primer for pharmacists. Can Pharm J (Ott). 2016;149(5):268-273.

  99. Feldman GJ, Sousa AR, Lipson DA, Tombs L, Barnes N, Riley JH, et al. Comparative Efficacy of Once-Daily Umeclidinium/Vilanterol and Tiotropium/Olodaterol Therapy in Symptomatic Chronic Obstructive Pulmonary Disease: A Randomized Study. Adv Ther. 2017;34(11):2518-2533.

  100. Rehabilitation AACVPR. Guidelines for pulmonary rehabilitation programs. Human Kinetics; 2011.

  101. CENETEC. Oxigenoterapia crónica ambulatoria en edad adulta y pediátrica en los tres niveles de atención. México; 2015.

  102. Gassner LA, Dunn S, Piller N. Aerobic exercise and the post myocardial infarction patient: a review of the literature. Heart Lung 2003;32(4):258-265.

  103. Clark AM, Hartling L, Vandermeer B, McAlister FA. Meta-analysis: secondary prevention programs for patients with coronary artery disease. Ann Intern Med 2005;143(9):659-672.

  104. Walters JA, Tan DJ, White CJ, Wood-Baker R. Different durations of corticosteroid therapy for exacerbations of chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2018;3:CD006897.

  105. Cheng T, Gong Y, Guo Y, et al. Systemic corticosteroid for COPD exacerbations, whether the higher dose is better? A meta-analysis of randomized controlled trials. Clin Respir J 2013;7(4):305-318.

  106. Abroug F, Ouanes I, Abroug S, et al. Systemic corticosteroids in acute exacerbation of COPD: a meta-analysis of controlled studies with emphasis on ICU patients. Ann Intensive Care 2014;4:32.

  107. Albert RK, Connett J, Bailey WC, et al. Azithromycin for prevention of exacerbations of COPD. N Engl J Med 2011;365(8):689-698.

  108. Sethi S, Jones PW, Theron MS, et al. Pulsed moxifloxacin for the prevention of exacerbations of chronic obstructive pulmonary disease: a randomized controlled trial. Respir Res 2010;11:10.

  109. Vollenweider DJ, Frei A, Steurer-Stey CA, Garcia-Aymerich J, Puhan MA. Antibiotics for exacerbations of chronic obstructive pulmonary disease. Cochrane Database Syst Rev 2018;10:CD010257.

  110. Medicine TLR. The death of low-dose oral theophylline for COPD? Lancet Respir Med. 2018 Jul;6(7):479. doi: 10.1016/S2213-2600(18)30240-6.

  111. Strickland SL, Rubin BK, Haas CF, Volsko TA, Drescher GS, O’Malley CA. AARC clinical practice guideline: effectiveness of pharmacologic airway clearance therapies in hospitalized patients. Respir Care 2015;60(7):1071-1077. Available from: http://rc.rcjournal.com/cgi/doi/10.4187/respcare.04165




2020     |     www.medigraphic.com